Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study
Abstract Background Territorial differences in the access to innovative anticancer drugs have been reported from many countries. The objectives of this study were to evaluate access to innovative treatments for metastatic lung cancer in France, and to assess whether socioeconomic indicators were pre...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-10-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-018-4958-5 |
id |
doaj-ad3734f99b804fe788808c1c80bb3664 |
---|---|
record_format |
Article |
spelling |
doaj-ad3734f99b804fe788808c1c80bb36642020-11-25T01:43:59ZengBMCBMC Cancer1471-24072018-10-011811810.1186/s12885-018-4958-5Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE studyArnaud Scherpereel0Isabelle Durand-Zaleski1François-Emery Cotté2Jérôme Fernandes3Didier Debieuvre4Cécile Blein5Anne-Françoise Gaudin6Charlène Tournier7Alexandre Vainchtock8Pierre Chauvin9Pierre-Jean Souquet10Virginie Westeel11Christos Chouaïd12Pulmonary and Thoracic Oncology Department, CHU de Lille, Lille UniversityURCEco Île-de-France, Hôtel-Dieu HospitalHealth Economics and Outcomes Research, Laboratoire Bristol-Myers SquibbOC SantéDepartment of Chest Medicine, GHRMSA, Emile Muller HospitalHEVAHealth Economics and Outcomes Research, Laboratoire Bristol-Myers SquibbHEVAHEVAInstitut Pierre Louis d’Epidémiologie et de Santé Publique (IPLESP UMRS 1136), Department of Social Epidemiology, Sorbonne Universités, UPMC Université Paris 06, INSERMDepartment of Chest Medicine, Hospices Civils de Lyon, Centre Hospitalier Lyon SudDepartment of Chest Medicine, Jean Minjoz University HospitalDepartment of Chest Medicine, Créteil University HospitalAbstract Background Territorial differences in the access to innovative anticancer drugs have been reported from many countries. The objectives of this study were to evaluate access to innovative treatments for metastatic lung cancer in France, and to assess whether socioeconomic indicators were predictors of access at the level of the municipality of residence. Methods All incident cases of metastatic lung cancer hospitalised for a chemotherapy in public hospitals in 2011 were identified from the French National Hospital discharge database. Information on prescription of innovative drugs from an associated database (FICHCOMP) was crossed with the population density of the municipality and a social deprivation index based on national census data. Results Overall, 21,974 incident cases of metastatic lung cancer were identified, all of whom were followed for 2 years. Of the 11,486 analysable patients receiving chemotherapy in the public sector, 6959 were treated with a FICHCOMP drug at least once, principally pemetrexed. In multivariate analysis, prescription of FICHCOMP drugs was less frequent in patients ≥66 years compared to those ≤55 years (odds ratio: 0.49 [0.44–0.55]), in men compared to women (0.86 [0.79–0.94]) and in patients with renal insufficiency (0.55 [0.41–0.73]) and other comorbidities. Prescription rates were also associated with social deprivation, being lowest in the most deprived municipalities compared to the most privileged municipalities (odds ratio: 0.82 [0.72–0.92]). No association was observed between the population density of the municipality and access to innovative drugs. Conclusion Although access to innovative medication in France seems to be relatively equitable, social deprivation is associated with poorer access. The reasons for this need to be investigated and addressed.http://link.springer.com/article/10.1186/s12885-018-4958-5Metastatic lung cancerInnovative treatmentsFranceSocial deprivation |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Arnaud Scherpereel Isabelle Durand-Zaleski François-Emery Cotté Jérôme Fernandes Didier Debieuvre Cécile Blein Anne-Françoise Gaudin Charlène Tournier Alexandre Vainchtock Pierre Chauvin Pierre-Jean Souquet Virginie Westeel Christos Chouaïd |
spellingShingle |
Arnaud Scherpereel Isabelle Durand-Zaleski François-Emery Cotté Jérôme Fernandes Didier Debieuvre Cécile Blein Anne-Françoise Gaudin Charlène Tournier Alexandre Vainchtock Pierre Chauvin Pierre-Jean Souquet Virginie Westeel Christos Chouaïd Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study BMC Cancer Metastatic lung cancer Innovative treatments France Social deprivation |
author_facet |
Arnaud Scherpereel Isabelle Durand-Zaleski François-Emery Cotté Jérôme Fernandes Didier Debieuvre Cécile Blein Anne-Françoise Gaudin Charlène Tournier Alexandre Vainchtock Pierre Chauvin Pierre-Jean Souquet Virginie Westeel Christos Chouaïd |
author_sort |
Arnaud Scherpereel |
title |
Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study |
title_short |
Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study |
title_full |
Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study |
title_fullStr |
Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study |
title_full_unstemmed |
Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study |
title_sort |
access to innovative drugs for metastatic lung cancer treatment in a french nationwide cohort: the territoire study |
publisher |
BMC |
series |
BMC Cancer |
issn |
1471-2407 |
publishDate |
2018-10-01 |
description |
Abstract Background Territorial differences in the access to innovative anticancer drugs have been reported from many countries. The objectives of this study were to evaluate access to innovative treatments for metastatic lung cancer in France, and to assess whether socioeconomic indicators were predictors of access at the level of the municipality of residence. Methods All incident cases of metastatic lung cancer hospitalised for a chemotherapy in public hospitals in 2011 were identified from the French National Hospital discharge database. Information on prescription of innovative drugs from an associated database (FICHCOMP) was crossed with the population density of the municipality and a social deprivation index based on national census data. Results Overall, 21,974 incident cases of metastatic lung cancer were identified, all of whom were followed for 2 years. Of the 11,486 analysable patients receiving chemotherapy in the public sector, 6959 were treated with a FICHCOMP drug at least once, principally pemetrexed. In multivariate analysis, prescription of FICHCOMP drugs was less frequent in patients ≥66 years compared to those ≤55 years (odds ratio: 0.49 [0.44–0.55]), in men compared to women (0.86 [0.79–0.94]) and in patients with renal insufficiency (0.55 [0.41–0.73]) and other comorbidities. Prescription rates were also associated with social deprivation, being lowest in the most deprived municipalities compared to the most privileged municipalities (odds ratio: 0.82 [0.72–0.92]). No association was observed between the population density of the municipality and access to innovative drugs. Conclusion Although access to innovative medication in France seems to be relatively equitable, social deprivation is associated with poorer access. The reasons for this need to be investigated and addressed. |
topic |
Metastatic lung cancer Innovative treatments France Social deprivation |
url |
http://link.springer.com/article/10.1186/s12885-018-4958-5 |
work_keys_str_mv |
AT arnaudscherpereel accesstoinnovativedrugsformetastaticlungcancertreatmentinafrenchnationwidecohorttheterritoirestudy AT isabelledurandzaleski accesstoinnovativedrugsformetastaticlungcancertreatmentinafrenchnationwidecohorttheterritoirestudy AT francoisemerycotte accesstoinnovativedrugsformetastaticlungcancertreatmentinafrenchnationwidecohorttheterritoirestudy AT jeromefernandes accesstoinnovativedrugsformetastaticlungcancertreatmentinafrenchnationwidecohorttheterritoirestudy AT didierdebieuvre accesstoinnovativedrugsformetastaticlungcancertreatmentinafrenchnationwidecohorttheterritoirestudy AT cecileblein accesstoinnovativedrugsformetastaticlungcancertreatmentinafrenchnationwidecohorttheterritoirestudy AT annefrancoisegaudin accesstoinnovativedrugsformetastaticlungcancertreatmentinafrenchnationwidecohorttheterritoirestudy AT charlenetournier accesstoinnovativedrugsformetastaticlungcancertreatmentinafrenchnationwidecohorttheterritoirestudy AT alexandrevainchtock accesstoinnovativedrugsformetastaticlungcancertreatmentinafrenchnationwidecohorttheterritoirestudy AT pierrechauvin accesstoinnovativedrugsformetastaticlungcancertreatmentinafrenchnationwidecohorttheterritoirestudy AT pierrejeansouquet accesstoinnovativedrugsformetastaticlungcancertreatmentinafrenchnationwidecohorttheterritoirestudy AT virginiewesteel accesstoinnovativedrugsformetastaticlungcancertreatmentinafrenchnationwidecohorttheterritoirestudy AT christoschouaid accesstoinnovativedrugsformetastaticlungcancertreatmentinafrenchnationwidecohorttheterritoirestudy |
_version_ |
1725030471640809472 |